MAPT and Alzheimer disease: These findings are consistent with recent work demonstrating that CSF and plasma pTau-217 had the tightest agreement compared with that for pTau-231 and pTau-181.22 Given its high diagnostic accuracy for tau and Aβ pathology, plasma pTau-217 may reduce the need for lumbar punctures when screening for AD risk and determining participant eligibility for disease-modifying therapy.5,6,42